REG - MyHealthChecked PLC - Partnership agreement with Patients Know Best

MyhealthcheckedAnnouncement

23/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250723:nRSW1131Sa&default-theme=true

RNS Number : 1131S  MyHealthChecked PLC  23 July 2025

MyHealthChecked PLC

("MyHealthChecked" or the "Company")

 

Partnership agreement with Patients Know Best

Over-the-counter health test results now accessible via the NHS App

 

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company,
announces that it has signed a partnership agreement with Patients Know Best
("PKB") to enable customers using at-home Blood and DNA tests from
MyHealthChecked to access their laboratory test results via the NHS App.

 

The agreement between the Company's trading subsidiary, Concepta Diagnostics
Limited and PKB, is for an initial term of 3 years and defines the rights and
obligations of the parties in relation to the MyHealthChecked laboratory
portfolio. From today, customers of MyHealthChecked can choose to upload their
health check results to PKB and access these via the NHS App, helping them
have a single source of health information. The option to upload is available
to those purchasing directly from MyHealthChecked or its retail distributors,
in regions where PKB is live with the NHS App. Currently, this includes 22 of
the Integrated Care Systems in England and one Health Board in Wales.

 

Commenting on the collaboration, Penny McCormick, CEO at MyHealthChecked,
said: "Our partnership with PKB is integral in helping us support customers to
make informed decisions about their health, and we hope that over time, this
may go some way to easing the pressure on the health system. Providing a
single location to access personal health information is a very exciting
development in our strategy to support the nation's health, and we are proud
to have delivered this with the fantastic and passionate team at PKB."

 

For further information contact:

 

 MyHealthChecked plc                                                               www.myhealthchecked.com (http://www.myhealthchecked.com)
 Penny McCormick, Chief Executive Officer                                          via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                                           Tel: +44 (0)20 3368 3550
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited (Broker)                         Tel: +44 (0)20 3903 7715
 David Poutney / Nicholas Chambers

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                   (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus / Alice Woodings                            Mob: +44 (0)7980 541 893 / +44(0)7407 804 654

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com) )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.

 

MyHealthChecked (http://www.myhealthchecked.com) is the umbrella brand of a
range of at-home rapid tests, as well as DNA, RNA and blood sample collection
kits which have been created to support customers on their journeys to
wellness. The tests are lateral-flow self-tests, whilst the sample collection
kits enable the collection of blood, urine, nasal or mouth swab samples that
are analysed in partner laboratories for a range of biomarkers. The tests have
been made available online and for over-the-counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFLFIEDSIFFIE